Piper Sandler Raises Becton, Dickinson and Company (NYSE:BDX) Price Target to $175.00

Becton, Dickinson and Company (NYSE:BDX) had its price target raised by investment analysts at Piper Sandler from $161.00 to $175.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. Piper Sandler’s price target would suggest a potential downside of 0.53% from the company’s current price.

Several other research analysts have also recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America decreased their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $186.87.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded down $1.14 on Friday, reaching $175.93. The stock had a trading volume of 606,197 shares, compared to its average volume of 2,707,575. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The company has a market cap of $48.48 billion, a P/E ratio of 44.54, a price-to-earnings-growth ratio of 12.16 and a beta of 0.19. The firm has a fifty day moving average of $153.78 and a two-hundred day moving average of $162.41.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.53 EPS for the current year.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,189 shares of company stock worth $765,661 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently modified their holdings of the company. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Becton, Dickinson and Company by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock worth $122,403,000 after acquiring an additional 26,671 shares in the last quarter. Cooke & Bieler LP lifted its stake in shares of Becton, Dickinson and Company by 27.2% in the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after purchasing an additional 240,673 shares during the period. KLP Kapitalforvaltning AS lifted its stake in shares of Becton, Dickinson and Company by 61.2% in the 4th quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock valued at $33,493,000 after purchasing an additional 65,500 shares during the period. Finally, Third View Private Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $4,992,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Fiscal third-quarter results beat expectations. BD reported adjusted EPS of $3.23 versus the $3.14 consensus and revenue of approximately $5.0 billion versus estimates of $4.89 billion. Revenue increased 5.4% year over year, supported by growth across its Medical Essentials and Interventional segments. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.620 to $12.720, above the $12.56 analyst consensus, and expects revenue growth toward the high end of its prior range. Year-to-date operating cash flow rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Neutral Sentiment: Analyst support remains cautious. Wells Fargo raised its price target from $161 to $170 but maintained an “equal weight” rating. The new target still implies roughly 3% downside from the referenced share price, limiting the positive impact of the earnings beat. Wells Fargo BDX Price Target Update
• Negative Sentiment: Profitability showed signs of pressure. Although revenue and adjusted EPS exceeded estimates, quarterly EPS declined from $3.68 a year earlier, while gross and operating margins weakened. Investors may view those trends as a risk to the durability of BD’s earnings growth.
• Negative Sentiment: Product-safety concerns add risk. BD reportedly recalled vascular-access-system needles following four patient deaths, creating potential regulatory, legal and reputational risks. BD Recalls Vascular Access System Needles

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.